Composition for the treatment of psoriasis and stress-related illnesses

Abstract

A composition for the combined treatment of psoriasis, stress and sleep disorders, the composition comprising: Acacia catechu extract in a quantity of approximately 50 mg; Bacopa monnieri extract in a quantity of approximately 150 mg; Piper longum extract in an amount of approximately 25 mg; Piper nigrum extract in an amount of approximately 25 mg; Ocimum basil extract in an amount of approximately 50 mg; Convolvulus pluricaulis extract in a quantity of approximately 150 mg.

Description

Technical field

[0001] The present invention relates to the field of Ayurvedic medicines. More precisely, it relates to synergistic herbal formulations made from plant extracts with therapeutic effects for the treatment of psoriasis, for improving skin health, for stress reduction, for improving sleep quality and related physiological disorders. Background of the invention

[0002] Psoriasis is a chronic, relapsing inflammatory skin disease characterized by erythematous plaques, scaling, and immunodeficiency. While modern pharmacological treatments such as corticosteroids, immunosuppressants, and biologics are effective, they are associated with high costs and significant side effects, including liver toxicity, nephrotoxicity, and systemic immunosuppression. Therefore, there is a great need for safe, natural, and cost-effective remedies.

[0003] Ayurvedic medicine has long used a variety of herbal remedies to treat skin and neurological conditions. Acacia catechu has been known for its wound-healing and anti-inflammatory properties. Bacopa monnieri and Convolvulus pluricaulis are well-documented nootropics with stress-relieving effects. Piper longum and Piper nigrum contribute to improved bioavailability of phytochemicals and possess anti-inflammatory potential. Ocimum basilicum is known for its immunomodulatory and antioxidant functions. Similarly, Withania somnifera, Valerian jatamansi, Nardostachys jatamansi, and Celastrus paniculatus are widely known for their adaptogenic, anxiolytic, and calming effects, which improve sleep quality and reduce stress.

[0004] Existing Ayurvedic formulas, however, either focus primarily on individual herbs or lack scientifically balanced synergistic combinations that target both skin inflammation (psoriasis) and neurophysiological imbalances (stress, insomnia). The present invention fills this gap by providing two different but related compositions: one specifically optimized for psoriasis recovery and another that reduces stress and improves sleep. Both utilize the synergistic activity of multiple plant compounds.

[0005] Psoriasis is a chronic, immune-mediated skin disease characterized by hyperproliferation of keratinocytes, thickening of the epidermis, inflammation, and scaling, affecting millions of people worldwide. The condition is not merely cosmetic but significantly impacts quality of life, causing pain, itching, social stigma, and psychological distress. In recent decades, medicine has developed a wide range of therapies for psoriasis, from topical corticosteroids and keratolytics to advanced biologic therapies. Despite this variety of available interventions, the disease remains challenging to treat due to its chronic and relapsing nature, multifactorial etiology, and systemic associations such as arthritis, metabolic syndrome, and cardiovascular disease.Each class of treatment has its own advantages, but all come with limitations that necessitate the exploration of safer, more holistic, and longer-lasting alternatives.

[0006] Topical corticosteroids are the most commonly prescribed treatment for mild to moderate psoriasis. They provide rapid relief by suppressing local inflammation and reducing erythema and scaling. However, they also have significant drawbacks. Prolonged use of corticosteroids can lead to skin atrophy, telangiectasia, striae, and even systemic absorption with suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Patients also frequently experience tachyphylaxis, a condition in which the steroid's effectiveness diminishes over time, necessitating higher doses or stronger formulations. The use of corticosteroids is particularly problematic in children and pregnant women due to systemic safety concerns. Thus, while topical steroids offer short-term symptom relief, they do not address the underlying causes of psoriasis and pose a high risk with chronic use.

[0007] Other topical agents such as coal tar, anthralin, salicylic acid, and calcipotriol (a vitamin D analogue) have been used. While coal tar preparations are inexpensive and effective in reducing scaling, patient compliance is low due to their unpleasant odor, staining, and cumbersome application. Anthralin frequently irritates the skin, limiting its use to short-term therapy. Calcipotriol and related vitamin D analogues effectively regulate keratinocyte proliferation but can cause skin irritation and hypercalcemia if overused. These agents provide partial symptom relief but rarely induce remission when used alone, highlighting their limited usefulness in moderate to severe cases.

[0008] Systemic therapies have been developed for moderate to severe psoriasis that does not respond to topical treatments. Methotrexate, an antimetabolite, remains a mainstay due to its immunosuppressive properties; however, long-term use is associated with liver toxicity, pulmonary fibrosis, and bone marrow suppression, necessitating regular monitoring through blood tests and liver biopsies. Cyclosporine, another systemic immunosuppressant, can induce remission but is nephrotoxic and associated with hypertension, an increased risk of malignancies, and a high relapse rate after discontinuation of treatment. Acitretin, an oral retinoid, helps normalize keratinocyte differentiation but is unsuitable for women of childbearing age due to its teratogenicity. Its side effects include mucosal dryness, hair loss, and hyperlipidemia.The common disadvantage of systemic drugs is that, although they allow for significant control of psoriasis symptoms, their safety profile precludes long-term continuous use and patients are prone to relapse after discontinuing treatment.

[0009] Over the past two decades, biologic therapies have revolutionized the treatment of psoriasis by targeting immunological pathways involved in the pathogenesis of the disease. Agents targeting tumor necrosis factor alpha (such as etanercept, adalimumab, and infliximab), interleukin-12 / 23 (ustekinumab), and interleukin-17 (secukinumab, ixekizumab) have demonstrated remarkable efficacy in reducing PASI (Psoriasis Area and Severity Index) scores and sometimes achieving complete remission in patients. Despite their success, biologics are associated with several significant drawbacks. They are prohibitively expensive, limiting their availability in low- and middle-income countries. Their immunosuppressive effects make patients susceptible to infections such as tuberculosis, fungal infections, and the reactivation of hepatitis.Long-term safety data continue to be monitored due to concerns about potential malignancy risks. Furthermore, a significant proportion of patients experience a primary or secondary non-response due to immunogenicity or pharmacokinetic variability, necessitating a drug change or combination therapy. Biologics thus represent an effective tool, but are by no means a universal solution.

[0010] Phototherapy, including narrowband UVB and psoralen plus UVA (PUVA), is another established approach. It allows for large-area irradiation of the skin and can induce remission, but requires frequent hospitalizations, often two to three times per week, which affects patient compliance. Long-term phototherapy increases the risk of photoaging and carcinogenesis, particularly of squamous cell carcinoma. Furthermore, phototherapy is contraindicated in patients with photosensitivity disorders and is unsuitable for patients with busy lifestyles or limited access to specialized facilities. Although effective, the inconvenience and long-term risks make it less suitable for sustained treatment.

[0011] From a psychosocial perspective, the psychological dimension of psoriasis is largely neglected in conventional therapies. Patients often suffer from depression, anxiety, and social withdrawal due to visible skin lesions. Stress is also a known trigger and aggravating factor for psoriasis flare-ups. This creates a vicious cycle in which stress worsens the disease and the disease worsens the stress. While biologics and systemic medications suppress inflammation, they do not address this psychosomatic component. The integration of stress management into therapy is poorly understood, leaving a significant gap in holistic care.

[0012] Alongside psoriasis-specific therapies, there is a growing trend toward researching natural and herbal remedies. Various herbal remedies such as turmeric (curcumin), neem, aloe vera, and other herbal preparations are used in traditional systems like Ayurveda, Unani, and Chinese medicine. These remedies often exhibit anti-inflammatory, antioxidant, and immunomodulatory properties with comparatively fewer side effects than synthetic drugs. However, existing herbal preparations frequently suffer from a lack of standardization, fluctuating raw material quality, variations in the content of active phytochemicals, and a lack of rigorous clinical validation. Many are marketed as dietary supplements rather than approved drugs, leading to skepticism within conventional medicine and lower acceptance in formal clinical practice.

[0013] One of the biggest challenges with formulations containing only one or more herbs is the limited bioavailability of the active ingredients. Compounds such as curcumin and bacosides are known to be poorly soluble and poorly absorbed, which reduces their clinical efficacy. Furthermore, herbal medicines without synergistic adjuncts often offer only modest benefits compared to the rapid relief provided by allopathic medications, leading to patient dissatisfaction. Therefore, there is a significant need for synergistic formulations containing multiple herbs, where certain components not only exert therapeutic effects but also enhance the bioavailability and systemic efficacy of others. For example, piperine from black pepper is known to significantly improve the absorption of several phytochemicals, yet its integration into formulations for psoriasis or stress remains limited.

[0014] Another disadvantage of existing natural remedies is their lack of specificity. Many herbal mixtures are marketed with general promises such as "blood purification" or "improved skin health," but lack a targeted formulation that addresses specific mechanisms of psoriasis, such as T-cell-mediated inflammation, keratinocyte hyperproliferation, or oxidative stress mechanisms.

[0015] Without mechanistic precision, the results of such treatments are inconsistent, and their acceptance within the scientific and regulatory framework remains limited. Clinical trials are often small-scale, uncontrolled, or anecdotal, further restricting their credibility.

[0016] In addition to the shortcomings of psoriasis-specific treatments, stress and insomnia represent important comorbidities and triggers that are inadequately addressed in existing therapeutic paradigms. Conventional allopathic options for stress and sleep disturbances include benzodiazepines, antidepressants, and sedative-hypnotics, which, while effective in the short term, carry the risk of dependence, tolerance, cognitive impairment, and systemic side effects. Herbal sedatives such as valerian root, passionflower, and chamomile are safer but often too mild when used alone. There is a clear unmet need for herbal formulations that combine multiple adaptogens, anxiolytics, and cognitive enhancers to provide comprehensive relief from stress and insomnia while being safe for long-term use.

[0017] Existing treatment methods for psoriasis and related stress-related disorders therefore exhibit numerous shortcomings. While allopathic medications alleviate symptoms, they carry significant risks and offer no holistic benefit. Phototherapy is inconvenient and risky in the long term. Biologics are expensive, difficult to access, and not universally effective. Herbal remedies, while safer, are insufficiently standardized and validated. Furthermore, conventional medicine inadequately considers the interplay between psoriasis and stress, leaving patients trapped in a cycle of recurring flare-ups and psychological distress.These limitations provide a strong incentive for the development of novel, standardized, and scientifically balanced multi-herbal formulas that not only address the dermatological and immunological aspects of psoriasis but also alleviate stress and improve neurological balance. By developing compositions with carefully selected herbs such as Acacia catechu, Bacopa monnieri, Piper longum, Piper nigrum, Ocimum basilicum, Convolvulus pluricaulis, Withania somnifera, Valerian jatamansi, Acorus calamus, Celastrus paniculatus, and Nardostachys jatamansi, it becomes possible to create synergistic interventions that are safe, effective, and holistic, addressing both the physiological and psychosomatic dimensions of the disease. Summary of the invention

[0018] The invention provides a first composition comprising a synergistic mixture of Acacia catechu, Bacopa monnieri, Piper longum, Piper nigrum, Ocimum basilicum, and Convolvulus pluricaulis, optimized for improving skin health and treating psoriasis. A second composition contains Withania somnifera, Bacopa monnieri, Valeriana jatamansi, Piper longum, Acorus calamus, Celastrus paniculatus, and Nardostachys jatamansi, optimized for stress reduction and improving sleep quality.

[0019] The invention further relates to the production of these compositions in pharmaceutically acceptable dosage forms, such as capsules, tablets, decoctions, or powders. The production process includes the extraction of phytochemicals, mixing in controlled ratios, and stabilization of the composition to maintain its efficacy. Treatment methods are also described, including the oral administration of the compositions to individuals suffering from psoriasis, stress, insomnia, or related conditions.

[0020] The main objective of the present invention is to provide a novel, scientifically standardized Ayurvedic composition that offers a safe and effective therapeutic alternative for the treatment of psoriasis and stress-related disorders. The invention aims to overcome the disadvantages of existing conventional therapies such as corticosteroids, immunosuppressants, biologics, and phototherapy, which, while effective, are limited by severe side effects, high costs, or a lack of long-term safety. By utilizing carefully selected plant extracts with complementary pharmacological properties, the invention is intended to provide a holistic solution that not only alleviates the skin inflammation and scaling associated with psoriasis but also regulates the underlying immunological and neuropsychological imbalances that exacerbate the condition.

[0021] Another important objective of the invention is to provide a synergistic multi-herb formulation in which certain components act as bioenhancers, enhancing the absorption and systemic efficacy of other phytochemicals. For example, the addition of Piper longum and Piper nigrum increases the bioavailability of bioactive compounds such as bacosides and catechins, thereby improving therapeutic outcomes at lower doses and reducing the need for synthetic adjuvants. This targeted synergy addresses one of the major drawbacks of conventional herbal remedies, which often suffer from low bioavailability and inconsistent efficacy.

[0022] A further aim of the invention is to provide compositions that simultaneously address the psychosomatic dimensions of psoriasis through the inclusion of adaptogenic and neuroprotective herbs. Stress, anxiety, and insomnia are known triggers and comorbidities that exacerbate psoriasis pathology. By including herbs such as Bacopa monnieri, Convolvulus pluricaulis, Withania somnifera, Valerian jatamansi, and Nardostachys jatamansi, the compositions not only reduce systemic stress levels and promote restful sleep, but also indirectly contribute to decreasing the frequency and severity of psoriasis flare-ups. This dual-action approach ensures comprehensive treatment of both the dermatological symptoms and their psychological causes.

[0023] The invention also aims to provide a composition suitable for long-term use that avoids the toxicological risks of synthetic drugs. By using standardized extracts of plant substances traditionally recognized as safe, the formulation can be administered continuously, thus offering sustainable disease treatment and improved patient compliance. The invention therefore meets the need for a therapy that maintains remission and quality of life without exposing patients to organ damage, carcinogenesis, or systemic immunosuppression.

[0024] Another objective of the invention is the development of formulations that can be offered in pharmaceutically acceptable dosage forms such as capsules, tablets, powders, or decoctions, thus ensuring ease of use and patient acceptance. The compositions are designed to be shelf-stable, palatable, and safe for use in adults. Clear dosage guidelines optimize therapeutic efficacy while minimizing risks.

[0025] Overall, the objectives of the present invention are to create a holistic, effective, and scientifically validated Ayurvedic composition that bridges the gap between traditional knowledge and modern therapeutic requirements. By providing a treatment method that integrates psoriasis and stress, the invention aims to offer a long-term, patient-friendly, and accessible healthcare solution that significantly improves clinical outcomes and the quality of life of those affected. Detailed description of the invention

[0026] It is understood, however, that this does not intend to limit the scope of the invention, since such changes and further modifications of the system shown and such further applications of the principles of the invention as they are shown therein are taken into consideration as would normally occur to a person skilled in the art in the field to which the invention relates.

[0027] It is clear to the person skilled in the art that the preceding general description and the following detailed description are exemplary and explanatory of the invention and are not intended as a limitation of it.

[0028] References in this specification to “an aspect”, “another aspect”, or similar expressions mean that a particular feature, structure, or property described in connection with the embodiment is included in at least one embodiment of the present disclosure. Therefore, occurrences of the expressions “in one embodiment”, “in another embodiment”, and similar expressions in this specification may all refer to the same embodiment, but need not.

[0029] The terms "includes," "include," or other variations thereof are intended to cover non-exclusive inclusion, such that a process or method that includes a list of steps may not only contain those steps but may also include other steps not expressly listed or inherent in such process or method. Likewise, the statement "includes..." in the case of one or more devices, subsystems, elements, structures, or components does not, without further limitations, preclude the existence of other devices, subsystems, elements, structures, components, or additional devices, subsystems, elements, structures, or components.

[0030] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as understood by a person skilled in the art in the field of the invention. The system, methods, and examples provided here serve only for illustration and are not to be construed as a limitation.

[0031] The present invention provides an Ayurvedic pharmaceutical composition for the combined treatment of psoriasis, stress and sleep disorders, the composition comprising the following: Acacia catechu extract in a quantity of approximately 50 mg; Bacopa monnieri extract in a quantity of approximately 150 mg; Piper longum extract in an amount of approximately 25 mg; Piper nigrum extract in an amount of approximately 25 mg; Ocimum basil extract in an amount of approximately 50 mg; Convolvulus pluricaulis extract in a quantity of approximately 150 mg.

[0032] In one embodiment, Withania somnifera extract is standardized to 5-10% withanolides to provide adaptogenic and anti-stress activity.

[0033] In one embodiment, Bacopa monnieri extract consists of 40-60% bacosides and offers neuroprotective and immunomodulatory effects for the combined treatment of psoriasis and stress.

[0034] In one embodiment, Piper longum and Piper nigrum (108) act as bioavailability enhancers to increase the systemic absorption of catechins, bacosides and withanolides.

[0035] In one embodiment, the oral dosage form is a capsule containing approximately 450 mg to 600 mg of the combined extracts, administered twice daily.

[0036] In one embodiment, the composition further comprises Withania somnifera extract in an amount of approximately 100-200 mg.

[0037] In one embodiment, the composition further comprises Valeriana Jatamansi extract in an amount of approximately 75-150 mg.

[0038] In one embodiment, the composition further comprises Acorus calamus extract in an amount of approximately 25-75 mg.

[0039] In one embodiment, the composition further comprises Celastrus paniculatus extract in an amount of approximately 50-100 mg.

[0040] In one embodiment, the composition further comprises Nardostachys Jatamansi extract in an amount of approximately 75-150 mg.

[0041] In one embodiment, the present invention provides a system for synthesizing the Ayurvedic pharmaceutical composition, the system comprising: an extraction unit configured to extract standardized herbal extracts of Acacia catechu, Bacopa monnieri, Piper longum, Piper nigrum, Ocimum basilicum, and Convolvulus pluricaulis using solvent extraction and drying techniques; a concentration and purification unit configured to standardize active biomolecules, including catechins, bacosides, and piperine; a mixing unit configured to mix the standardized extracts in predetermined amounts to form a homogeneous formulation; and a dosing unit configured to encapsulate or tablet the mixed extracts with pharmaceutically acceptable excipients.the system ensures batch consistency, optimized bioavailability, and stability of the final composition.

[0042] The present invention relates to an Ayurvedic pharmaceutical composition and treatment method for the simultaneous treatment of dermatological, neuroendocrine, and sleep-related disorders, in particular psoriasis, stress, and sleep disturbances. The composition is based on a synergistic combination of eleven herbal extracts: Acacia catechu, Bacopa monnieri, Piper longum, Piper nigrum, Ocimum basilicum, Convolvulus pluricaulis, Withania somnifera, Valerian jatamansi, Acorus calamus, Celastrus paniculatus, and Nardostachys jatamansi. Each of these components contributes to different pharmacological activities, and when combined in specific proportions, they form a multi-target therapeutic algorithm capable of addressing the interconnected pathological pathways linking psoriasis, stress, and sleep disturbances.

[0043] The therapeutic algorithm of the invention can be understood in terms of three interdependent levels: immunomodulation and anti-inflammatory effects in psoriasis, adaptogenic and neuroprotective regulation for stress management, and sedative-nootropic effects for improved sleep. At the dermatological level, Acacia catechu provides high concentrations of catechins that suppress inflammatory mediators such as TNF-α, IL-6, and IL-17, which are directly involved in the formation of psoriatic plaques. This activity is algorithmically enhanced by Bacopa monnieri, which modulates T-cell function and downregulates cytokine cascades, thereby restoring immunological homeostasis. The inclusion of Piper longum and Piper nigrum ensures optimized intestinal absorption and systemic bioavailability of these bioactive compounds and constitutes the first step of the therapeutic algorithm.

[0044] At the neuroendocrine level, stress is managed through the adaptogenic activity of Withania somnifera, which regulates the hypothalamic-pituitary-adrenal (HPA) axis and lowers circulating cortisol levels. This adaptogenic effect is further enhanced by Celastrus paniculatus and Convolvulus pluricaulis, which exert nootropic and neuroprotective effects, improving stress resistance while simultaneously preventing neuroinflammatory exacerbations of psoriasis. The algorithm therefore ensures that systemic stress, known to trigger psoriasis severity, is actively mitigated alongside direct dermatological treatment.

[0045] At the level of sleep regulation, Valeriana jatamansi and Nardostachys jatamansi act as sedating neurotonics, modulating GABAergic activity, shortening sleep latency, and improving the depth and quality of restorative non-REM sleep. This sedating algorithmic function complements the stress-reducing effect of Withania somnifera by restoring circadian balance and counteracting insomnia, which is often associated with psoriasis and chronic stress. Acorus calamus is intended to stabilize the central nervous system, while Ocimum basilicum acts as an antioxidant and bronchodilator, thus promoting holistic physiological recovery.

[0046] The synergy of the invention is not achieved solely through individual effects, but through their orchestrated algorithmic sequence. When administered orally, the bioavailability-enhancing effect of Piper longum and Piper nigrum acts as the starting point of the algorithm. This is followed by immunological recalibration using Acacia catechu and Bacopa monnieri, which reduce inflammatory triggers of psoriasis. Simultaneously, Withania somnifera initiates stress regulation by modulating HPA axis activity, leading to reduced cortisol secretion. The subsequent stages of the algorithm utilize Valeriana jatamansi and Nardostachys jatamansi, which optimize sleep patterns and thus complete a cycle of physiological recovery. In parallel, Celastrus paniculatus, Convolvulus pluricaulis, and Acorus calamus serve as a stabilizing agent, strengthening cognitive balance, neuroprotection, and systemic resilience.

[0047] Clinical application of this algorithm demonstrates a dual benefit. Patients who received the formula twice daily for four to six weeks showed a visible reduction in psoriatic lesions, erythema, and itching, as well as a measurable decrease in perceived stress levels and serum cortisol levels, and significant improvements in sleep latency and sleep depth. The therapeutic algorithm thus integrates dermatological recovery with stress modulation and sleep normalization into a single, unified treatment strategy.

[0048] In summary, the invention offers a novel Ayurvedic therapeutic algorithm in the form of an herbal mixture that simultaneously treats psoriasis, stress, and sleep disorders. The algorithm utilizes synergistic interactions between herbal extracts to create a multi-target treatment system that restores skin health, balances neuroendocrine responses, and improves sleep architecture. The invention thus represents a comprehensive approach to treating interconnected chronic conditions through a scientifically sound herbal formulation. Composition 1: Recovery from psoriasis and skin health

[0049] The first embodiment of the invention provides a composition comprising the following: • Acacia catechu extract (50 mg): has anti-inflammatory and wound-healing properties and contributes to skin regeneration. • Bacopa Monnieri extract (150 mg): acts as a cognitive enhancer and stress modulator and indirectly supports immune regulation. • Piper longum extract (25 mg): supports digestion and bioavailability of other active ingredients. • Piper nigrum extract (25 mg): improves the absorption of phytochemicals through piperine activity. • Ocimum basil extract (50 mg): has antioxidant and immunomodulatory effects. • Convolvulus pluricaulis extract (150 mg): supports neurological balance and reduces stress-related exacerbation of psoriasis.

[0050] The combination exerts a synergistic effect, accelerating skin regeneration through both local anti-inflammatory mechanisms and systemic stress regulation. Composition 2: Stress reduction and sleep improvement

[0051] The second embodiment provides a composition comprising the following: • Withania Somnifera extract: a proven adaptogen that reduces stress and improves sleep quality. • Bacopa Monnieri extract (150 mg): improves memory, reduces anxiety and supports sleep regulation. • Valerian Jatamansi extract: has a calming and relaxing effect and helps with insomnia. • Piper longum extract (25 mg): supports digestion and increases the effect of herbs administered at the same time. • Acorus calamus extract: traditionally used for neurological and digestive problems and promotes sleep. • Celastrus Paniculatus extract: improves cognitive function and nervous system health. • Nardostachys Jatamansi extract: has a calming effect, helps regulate sleep and supports heart health.

[0052] The formulation improves neuroendocrine regulation, lowers cortisol levels and provides natural sedation without habit-forming effects.

[0053] Advantages, further benefits, and problem solutions have been described above with reference to specific embodiments. However, the advantages, benefits, problem solutions, and all components that can lead to an advantage, benefit, or solution occurring or becoming more apparent are not to be construed as critical, necessary, or essential features or components of individual or all claims.

Claims

[1] A composition for the combined treatment of psoriasis, stress and sleep disorders, comprising: Acacia catechu extract in a quantity of approximately 50 mg; Bacopa monnieri extract in a quantity of approximately 150 mg; Piper longum extract in an amount of approximately 25 mg; Piper nigrum extract in an amount of approximately 25 mg; Ocimum basil extract in an amount of approximately 50 mg; Convolvulus pluricaulis extract in a quantity of approximately 150 mg. [2] Composition according to claim 1, further comprising Withania Somnifera extract in an amount of about 100-200 mg. [3] Composition according to claim 1, further comprising Valeriana jatamansi extract in an amount of about 75-150 mg. [4] Composition according to claim 1, which furthermore contains Acorus calamus extract in an amount of about 25-75 mg. [5] Composition according to claim 1, further comprising Celastrus paniculatus extract in an amount of about 50-100 mg. [6] Composition according to claim 1, further comprising Nardostachys Jatamansi extract in an amount of about 75-150 mg. [7] A system for synthesizing the pharmaceutical composition, the system comprising: an extraction unit designed for the production of standardized herbal extracts from Acacia catechu, Bacopa monnieri, Piper longum, Piper nigrum, Ocimum basilicum and Convolvulus pluricaulis using solvent extraction and drying techniques; a concentration and purification unit configured for the standardization of active biomolecules such as catechins, bacosides and piperine; a mixing unit configured to mix the standardized extracts in predetermined quantities to form a homogeneous formulation; and a dosing unit configured to encapsulate or tablet the mixed extracts with pharmaceutically acceptable excipients; the system ensuring batch-to-batch consistency, optimized bioavailability, and stability of the final composition.